ERBB2 and familial pancreatic carcinoma: Although a large number of mutations exists in pancreatic cancer (including HER2/neu, K-RAS, Akt, p53, and p16INK4), clinical trials with erlotinib, cetuximab, and bevacizumab have yielded small clinical benefit [74, 75].